JOHANNESBURG, July 24 (Reuters) - South Africa's AspenPharmacare Holdings on Wednesday valued its bid for twoof GlaxoSmithKline's thrombosis drugs and a Frenchfactory at around 700 million pounds sterling, 100 millionpounds of which will be for inventory.
The proposed deal was announced last month, although neithercompany gave a value.